NTN Buzztime announced it received a letter from the NYSE Regulation stating that it is not in compliance with NYSE American LLC continued listing standards. Specifically, the company is not in compliance with Section 704 of the NYSE American Company Guide because it did not hold an annual meeting during the fiscal year ended December 31, 2020.

In a regulatory filing, Cloudera disclosed that its CEO Robert Bearden sold 141.8K shares of common stock on January 14th in a total transaction size of $2.03M, reducing his stake by about 18%.

Lockheed Martin was awarded a sole-source, cost-plus-incentive-fee, cost-plus-fixed-fee, firm-fixed-price definite contract under a Foreign Military Sales, or FMS, case to the United Arab Emirates, or UAE. The total value of this contract is $254.71M. Under this follow-on contract, the contractor will provide maintenance and sustainment for two Terminal High Altitude Area Defense batteries for UAE. The maintenance and sustainment scope of work includes providing logistics management, logistics product database, training, missile and ground repair and return, hardware/software development and sustainment, hardware in the loop, engineering services, missile field surveillance program and country unique specialty engineering for FMS client. The performance period is from January 15 through January 14, 2026. One offer was solicited and one offer was received. UAE FMS funds in the amount of $254,708,912 will be used to fund this effort. The Missile Defense Agency is the contracting activity.

Neovasc announced that it has received a "not-approvable" letter from U.S. Food & Drug Administration regarding its PMA submission for the Neovasc Reducer. Fred Colen, Neovasc CEO, said, "While we are disappointed in FDA's decision, the letter was not unexpected, given the outcome of the Panel meeting." He continued, "Millions of patients suffer from refractory angina, and for many, the Reducer offers hope for symptom relief. We will continue to evaluate our strategic options for bringing the Reducer to patients around the world." The FDA reviewed Reducer for treatment of patients with refractory angina pectoris despite guideline directed medical therapy, who are unsuitable for revascularization by coronary artery bypass grafting or by percutaneous coronary intervention. The Reducer is CE-marked in the European Union for the treatment of refractory angina.